BSX vs DXCM — Key Metrics

Metric BSX (BOSTON SCIENTIFIC CORP) DXCM (DEXCOM INC)
Price43.6482.52
Market Cap63.26 Billion30.78 Billion
P/E (TTM)18.3431.86
P/B (Quarterly)2.50611.758
P/S (TTM)3.06.03
Net Profit Margin (TTM)16.619.4
Gross Margin (TTM)69.163.4
ROE (TTM)13.936.5
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

BOSTON SCIENTIFIC CORP
vs
 
DEXCOM INC
 
BOSTON SCIENTIFIC CORP
vs
 
DEXCOM INC
Performance Comparison
AI Model Recommendation
BSX · BOSTON SCIENTIFIC CORP

Greatly Outperform

84
UnderperformOutperform
DXCM · DEXCOM INC

Outperform

13
UnderperformOutperform
Recommendation Summary

Stock BSX is projected to greatly outperform the market, stock DXCM is projected to outperform the market. Upfront Recommendation: BSX.

Financial Metrics
Prices delayed ~15 min
BSX Metrics DXCM
$43.64 Price $82.52
— Market Capitalization —
18.34 Price to Earnings Ratio 31.86
3.0 Price to Sales 6.03
18.99 Price to FCF Ratio 28.02
4.34 Price to Gross Profit 9.51
29.3 Price to R&D 50.61
7.75 Price to Current Assets 7.86

BSX vs DXCM at a glance

Boston Scientific Corp (BSX) and Dexcom INC (DXCM) are both Medical Devices companies in the Healthcare sector. BSX is the larger, at $63.3 billion in market value against $30.8 billion for DXCM, about 2.1 times the size.

On trailing-twelve-month figures, BSX trades at 18.3 times trailing earnings and DXCM at 31.9; net profit margins are 16.6% and 19.4%.

The Upfront Investment model currently rates BSX Greatly Outperform and DXCM Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.